Viviane Monges Sells 9,667 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Viviane Monges sold 9,667 shares of the firm’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $30.29, for a total value of $292,813.43. Following the transaction, the director owned 5,500 shares in the company, valued at approximately $166,595. This represents a 63.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Pharvaris Stock Up 0.7%

Shares of PHVS stock traded up $0.20 on Tuesday, hitting $29.88. The stock had a trading volume of 191,721 shares, compared to its average volume of 227,155. Pharvaris N.V. has a one year low of $15.46 and a one year high of $33.33. The business has a 50 day moving average price of $28.52 and a 200 day moving average price of $26.90. The company has a market cap of $1.95 billion, a PE ratio of -9.40 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.12. Equities research analysts expect that Pharvaris N.V. will post -3.25 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Pharvaris from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Citizens Jmp dropped their target price on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 13th. Citigroup reiterated a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Finally, Wolfe Research started coverage on Pharvaris in a research report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target for the company. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $49.18.

Institutional Trading of Pharvaris

A number of institutional investors have recently modified their holdings of PHVS. Tudor Investment Corp ET AL bought a new position in shares of Pharvaris during the 3rd quarter worth approximately $1,943,000. Patient Square Capital LP lifted its position in Pharvaris by 41.4% during the third quarter. Patient Square Capital LP now owns 345,381 shares of the company’s stock valued at $8,617,000 after acquiring an additional 101,098 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Pharvaris by 710.4% in the third quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock valued at $676,000 after acquiring an additional 23,743 shares in the last quarter. Integral Health Asset Management LLC purchased a new position in Pharvaris in the third quarter worth $4,990,000. Finally, Boothbay Fund Management LLC grew its holdings in Pharvaris by 735.1% in the third quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company’s stock worth $3,373,000 after purchasing an additional 118,994 shares during the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.